2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Sec61
  5. Sec61 Inhibitor

Sec61 Inhibitor

Sec61 Inhibitors (7):

Cat. No. Product Name Effect Purity
  • HY-139615
    Sec61-IN-1
    		Inhibitor 99.70%
    Sec61-IN-1 (compound A317) is a potent sec61 inhibitor that effectively targets glioma cells and enhances T cell cytotoxic effects[1][2].
  • HY-139617
    Sec61-IN-3
    		Inhibitor 99.22%
    Sec61-IN-2 (A3) is a protein secretion inhibitor (extracted from patent WO2020176863).
  • HY-139616
    Sec61-IN-2
    		Inhibitor 99.51%
    Sec61-IN-2 (A347) is a protein secretion inhibitor (extracted from patent WO2020176863).
  • HY-176763
    KZR-261
    		Inhibitor
    KZR-261 is a Sec61 translocase inhibitor. KZR-261 binds directly to the Sec61 channel, thereby inhibiting the biosynthesis of certain Sec61 substrate proteins, including oncogenic factors. KZR-261 activates the endoplasmic reticulum stress response. KZR-261 exhibits broad in vitro anticancer activity. KZR-261 shows antitumor efficacy in mouse models of cancer. KZR-261 can be used for the research of multiple myeloma, colorectal cancer, small cell lung cancer, pancreatic cancer, prostate cancer, non-Hodgkin's lymphoma, and mantle cell lymphoma.
  • HY-182674
    VGD020
    		Inhibitor
    VGD020 is a highly potent and selective Sec61 translocon inhibitor. VGD020 suppresses the expression of cell surface CD4 by inhibiting signal peptide-dependent co-translational ER translocation, interferes with the initiation of ER translocation of dengue virus polyprotein, and reduces the expression of Sortilin in breast cancer cells. VGD020 exhibits broad anti-flavivirus and anti-HIV activities. VGD020 can be used in research related to dengue virus infection, Zika virus infection, yellow fever virus infection, human immunodeficiency virus infection, and breast cancer.
  • HY-P10466A
    KZR-8445 TFA
    		Inhibitor
    KZR-8445 TFA, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 TFA binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 TFA inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 TFA inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 TFA blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 TFA can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection.
  • HY-P10466
    KZR-8445
    		Inhibitor
    KZR-8445, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection.